Interferon Beta-1A

Interferon Beta-1A is a recombinant glycoprotein consisting of 166 amino acids, identical to the natural human interferon beta. Produced in mammalian cells, it undergoes glycosylation, which is crucial for its biological activity. This cytokine modulates the immune response and is utilized in the treatment of multiple sclerosis.

The USP biologics proteins category provides critical standards and reference materials necessary for the development and manufacturing of therapeutic proteins. These proteins, which can be naturally derived or genetically engineered, are essential in treating various diseases and conditions, ensuring that they meet quality, safety, and efficacy standards.

The United States Pharmacopeia (USP) provides quality standards for biologics to ensure their safety, efficacy, and quality throughout the manufacturing process. These standards assist manufacturers in adhering to regulatory requirements and help safeguard public health by reducing risks associated with biologics.